News

Filter

Current filters:

ZometaPharmaceutical

1 to 9 of 10 results

Overview of Novartis' patent losses from GlobalData

11-10-2012

Swiss drug major Novartis (NOVN: VX) is the latest victim of patent protection loss, note analysts at…

DiovanFemaraFinancialGleevecNovartisPatentsPharmaceuticalReclastZometa

Novartis pulls application for an extended indication for Zometa in Europe

16-12-2010

Swiss drug major Novartis (NOVN: VX) has formally advised the European Medicines Agency (EMA) of its…

EuropeNovartisOncologyPharmaceuticalRegulationZometa

Novartis’ Zometa fails to meet Ph III primary endpoint in early breast cancer, stalling this indication; but Afinitor looks good

10-12-2010

Results from the second interim analysis of the Phase III AZURE (Adjuvant Zoledronic acid to redUce REcurrence)…

AfinitorNovartisOncologyPharmaceuticalResearchZometa

Analysts see positive future for Amgen’s bone metastases drug denosumab following strong Ph III data

10-02-2010

US biotechnology major Amgen received a boost recently when the company announced positive results from…

AmgenAnti-Arthritics/RheumaticsFinancialNovartisOncologyPharmaceuticalzoledronic acidZometa

1 to 9 of 10 results

COMPANY SPOTLIGHT

Menarini

Back to top